Journal Club
Quarterly Review of Publications by the GEST Research Committee
JOURNAL CLUB
Join GEST’s Research Committee as we review current publications and breakthrough research that can impact IR’s practice and patient outcomes. The Journal Club will meet virtually online once per quarter. To view past discussions, click here.
Upcoming: December 11, 2024 | 8:00 – 9:00 PM EST
Discussion:
Dr. Yuji Okuno will be discussing “Clinical results of ultrasound-guided intra-arterial embolization targeting abnormal neovessels for plantar fasciitis: 66 cases with up to 4 years of follow-up” in Foot and Ankle Surgery, July 2024. Review the publication here and register to join below.
Faculty
Dr. Shamar Young
University of Arizona
Dr. Yuji Okuno
Okuno Clinic
Dr. Ahmed Attia
University of Arizona
Dr. Osman Ahmed
University of Chicago
REGISTER
The Journal Club is Sponsored by
Contact
GEST Education
Past Journal Club Topics
Join GEST for a one-hour review of “Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial”.
The Partem trial is the first trial comparing Medical therapy to PAE. It was lead by Pr Marc Sapoval, MD PhD GEST founder and published in the Lancet.
It reflects the collaborative efforts of 10 centers where urologists and Interventional Radiologist are working together.
The positive outcome allows to propose PAE in case of failure of Alpha-blockers treatment in patients with BPH > 50 ml.
Faculty:
- Dr. Marc Sapoval, Hôpital Européen Georges-Pompidou
- Dr. Michael Borofsky, University of Minnesota
- Dr. Shivank Bhatia, University Of Miami Miller School Of Medicine
- Dr. Nassir Rostambeigi, Washington University School of Medicine
Educational Grant provided by Merit Medical
EPOCH (Evaluating TheraSphere in Patients with metastatic colorectal carcinoma Of the liver who have progressed on first-line Chemotherapy) is the first study to investigate the role of transarterial radioembolization with Yttrium-90 (TARE) when added to standard-of-care second-line chemotherapy for colorectal liver metastases.
Join the Journal Club on March 19th to listen to Dr Riad SALEM ‘s presentation of the study and its results on delayed disease progression, and, with our experts panel, follow the discussion of subset analyses to better identify the ideal patients who could benefit most, as well as dosimetric considerations to optimize the risk-benefit profile of TARE exposure.
Physician Faculty:
- Dr. Shamar Young, University of Arizona
- Dr. Beau Toskich, Mayo Clinic
- Dr. Mohammad Khreiss, University of Arizona
- Dr. Riad Salem, Feinberg School of Medicine
- Dr. Sudhir Manda, Arizona Oncology
Educational Grant provided by Boston Scientific